Therapeutic Target-Humanized Mice
Cre/Dre-Driver Mice
Immunodeficient NMG Mice
Cancer therapy advancements In vivo tumor models Preclinical cancer research Drug development in oncology Gene-modified cell lines Immuno-oncology Tumor modeling for drug discovery Cancer drug development Animal modeling services Cancer drug preclinical models
Join us for an insightful webinar exploring the critical role of in vivo tumor models in advancing cancer drug therapy. We will provide an overview of the diverse tumor models developed by our company, highlighting case studies demonstrating their effectiveness in preclinical cancer research. The session will delve into the comprehensive use of gene-modified cell lines and genetically modified spontaneous mouse models, showcasing their application in mimicking human cancer biology. We will conclude with a brief introduction to our company and our commitment to accelerating cancer drug development through innovative animal modeling services.
Our vision is to provide researchers all over the world with comprehensive, convenient and professional animal model services to facilitate a simplified and highly-efficient approach towards uncovering the mysteries of life.
inbreeding coefficient inbreeding depression FVB
U-HuDTMbase® is composed of more than 600 therapeutic target-humanized mouse models, including multiple background strains, and has covered almost all commonly studied areas, such as oncology, metabolism, immunity, inflammation and more.
mouse genome point mutation transgene
Shanghai Model Organisms
After the base is put into operation, SMOC’s capability to provide genetically modified rat/mouse models and technical services including gene function research and drug development will be greatly enhanced.
CRISPR-Cas9 technology Broad Institute genetically modified mouse
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Join us for an insightful webinar discussing advanced methodologies for generating monoclonal antibodies. This session will cover traditional and innovative approaches, highlighting their advantages and challenges.
Please fill in the order form and we will contact you within 2 working days.
